Morocco’s project to begin manufacturing Covid-19 vaccines locally began to materialize, a few months after the country signed several agreements in order to strengthen its biotechnological and industrial capacities.
Chinese pharmaceuticals company Sinopharm, Swedish giants Recipharm and three Moroccan banks will partner with the Moroccan state in this project, in addition to international biotechnology expert Samir Machour, currently vice president of Samsung Biologics.
The project can be broken down into three main components, the first being cooperation with Sinopharm concerning their vaccine, while the second relates to agreements with Recipharm on strengthening Morocco’s manufacturing capabilities.
The third component enables the state to take over Moroccan company Sothema’s facilities in order to begin manufacturing Sinopharm’s vaccine.
Accordingly, a company baptized Sensyo Pharmatech SA was founded by Mohammed VI Investment Fund, a consortium of three banks (Bank of Africa, Banque Centrale Populaire and Attijari Wafabank), Recipharm and Samir Machour, as announced by the Competition Council Saturday night.
The parties involved aim to build a Fill and Finish factory through Sensyo in order to manufacture vaccines and biotechnological products.
With a total investment of USD500 million, the project aims to enable Morocco to produce 5 million doses of Covid-19 vaccines a month initially, before progressively multiplying production, and eventually moving on to other vaccines.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.